Pyrrolyl Pyrazoline Carbaldehydes as Enoyl-ACP Reductase Inhibitors: Design, Synthesis and Antitubercular Activity
Sheshagiri R. Dixit1, Shrinivas D. Joshi1, *, Venkatarao H. Kulkarni1, Sunil S. Jalalpure2, 3, Vijay M. Kumbar3, Tulasigiriyappa Y. Mudaraddi3, Mallikarjuna N. Nadagouda1, Tejraj M. Aminabhavi1
Identifiers and Pagination:Year: 2017
First Page: 92
Last Page: 108
Publisher ID: TOMCJ-11-92
Article History:Received Date: 16/05/2017
Revision Received Date: 20/08/2017
Acceptance Date: 23/08/2017
Electronic publication date: 26/09/2017
Collection year: 2017
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In efforts to develop new antitubercular (anti-TB) compounds, herein we describe cytotoxic evaluation of 15 newly synthesized pyrrolyl pyrazoline carbaldehydes.
Method & Materials:
Surflex-Docking method was used to study binding modes of the compounds at the active site of the enzyme enoyl ACP reductase from Mycobacterium tuberculosis (M. tuberculosis), which plays an important role in FAS-II biosynthetic pathway of M. tuberculosis and also it is an important target for designing novel anti-TB agents.
Among the synthesized compounds, compounds 4g and 4i showed H-bonding interactions with MET98, TYR158 and co-factor NAD+, all of which fitted well within the binding pocket of InhA. Also, these compounds have shown the same type of interaction as that of 4TZK ligand. The compounds were further evaluated for preliminary anti-TB activities against M. tuberculosis H37Rv strain.
Some compounds were also screened for their mammalian cell toxicity using human lung cancer cell-line (A549) that was found to be nontoxic.